Behavioral-cognitive targets for cholinergic enhancement

Current Opinion in Behavioral Sciences

Volumn 4, Issue , 2015, Pages 22-26

  Sarter, Martin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2;

ASSOCIATION; ATTENTION; BEHAVIOR; BEHAVIORAL SCIENCE; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CHOLINERGIC SYNAPSE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; COGNITION; DRUG TARGETING; HUMAN; MENTAL TEST; NEUROMODULATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TASK PERFORMANCE;

EID: 84921535429     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2015.01.004     Document Type: Review

References (44)

1. Drachman D.A., Sahakian B.J. Memory and cognitive function in the elderly. A preliminary trial of physostigmine. Arch Neurol 1980, 37:674-675.
2. Drachman D.A., Leavitt J. Human memory and the cholinergic system. A relationship to aging?. Arch Neurol 1974, 30:113-121.
3. Deutsch J.A. The cholinergic synapse and the site of memory. Science 1971, 174:788-794.
4. Deutsch J.A., Leibowitz S.F. Amnesia or reversal of forgetting by anticholinesterase, depending simply on time of injection. Science 1966, 153:1017-1018.
5. Voytko M.L., Olton D.S., Richardson R.T., Gorman L.K., Tobin J.R., Price D.L. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 1994, 14:167-186.
6. McGaughy J., Kaiser T., Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical ache-positive fiber density. Behav Neurosci 1996, 110:247-265.
7. Muir J.L., Dunnett S.B., Robbins T.W., Everitt B.J. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res 1992, 89:611-622.
8. Bentley P., Driver J., Dolan R.J. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain 2008, 131:409-424.
9. Giacobini E., Zhu X.-D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996, 35:205-211.
10. Sarter M., Parikh V., Howe W.M. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci 2009, 10:383-390.
11. Moore H., Stuckman S., Sarter M., Bruno J.P. Potassium, but not atropine-stimulated cortical acetylcholine efflux, is reduced in aged rats. Neurobiol Aging 1996, 17:565-571.
12. Furey M.L., Pietrini P., Haxby J.V., Drevets W.C. Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology 2008, 33:913-923.
13. Herrero J.L., Roberts M.J., Delicato L.S., Gieselmann M.A., Dayan P., Thiele A. Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. Nature 2008, 454:1110-1114.
14. Sarter M., Tricklebank M. Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 2012, 11:423-424.
15. Posner M.I., Snyder C.R., Davidson B.J. Attention and the detection of signals. J Exp Psychol 1980, 109:160-174.
16. Turchi J., Sarter M. Cortical cholinergic inputs mediate processing capacity: effects of 192 IgG-saporin-induced lesions on olfactory span performance. Eur J Neurosci 2000, 12:4505-4514.
17. Botly L.C., De Rosa E. Cholinergic deafferentation of the neocortex using 192 IgG-saporin impairs feature binding in rats. J Neurosci 2009, 29:4120-4130.
18. Bucci D.J., Holland P.C., Gallagher M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J Neurosci 1998, 18:8038-8046.
19. St Peters M., Cherian A.K., Bradshaw M., Sarter M. Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP). Behav Brain Res 2011, 225:574-583.
20. Demeter E., Sarter M., Lustig C. Rats and humans paying attention: cross-species task development for translational research. Neuropsychology 2008, 22:787-799.
21. Kim K., Muller M.L., Bohnen N.I., Sarter M., Lustig C. Vulnerability to distraction in Parkinson's disease is linked to low cortical cholinergic function. Cognitive Neuroscience Society Annual Meeting Boston, MA 2014.
22. Howe W.M., Berry A.S., Francois J., Gilmour G., Carp J.M., Tricklebank M., Lustig C., Sarter M. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci 2013, 33:8742-8752.
23. Parikh V., Kozak R., Martinez V., Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron 2007, 56:141-154.
24. Parikh V., Ji J., Decker M.W., Sarter M. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 2010, 30:3518-3530.
25. Parikh V., Man K., Decker M.W., Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 2008, 28:3769-3780.
26. St Peters M., Demeter E., Lustig C., Bruno J.P., Sarter M. Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci 2011, 31:9760-9771.
27. Passetti F., Dalley J.W., O'Connell M.T., Everitt B.J., Robbins T.W. Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attentional task. Eur J Neurosci 2000, 12:3051-3058.
28. Paolone G., Angelakos C.C., Meyer P.J., Robinson T.E., Sarter M. Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J Neurosci 2013, 33:8321-8335.
29. Sarter M., Gehring W.J., Kozak R. More attention must be paid: the neurobiology of attentional effort. Brain Res Rev 2006, 51:145-160.
30. Sarter M., Paolone G. Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav Neurosci 2011, 125:825-835.
31. Sarter M., Kim Y. Interpreting chemical neurotransmission in vivo: techniques, time scales and theories. ACS Chem Neurosci 2015, (in press, Epub ahead of print).
32. Hasselmo M.E., Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011, 36:52-73.
33. Howe W.M., Ji J., Parikh V., Williams S., Mocaër E., Trocmé-Thibierge C., Sarter M. Enhancement of attentional performance by selective stimulation of alpha4beta2* nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010, 35:1391-1401.
34. Apostol G., Abi-Saab W., Kratochvil C.J., Adler L.A., Robieson W.Z., Gault L.M., Pritchett Y.L., Feifel D., Collins M.A., Saltarelli M.D. Efficacy and safety of the novel α(4)β(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 2011, 219:715-725.
35. Bain E.E., Robieson W., Pritchett Y., Garimella T., Abi-Saab W., Apostol G., McGough J.J., Saltarelli M.D. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology 2013, 38:405-413.
36. Sarter M., Lustig C., Howe W.M., Gritton H., Berry A.S. Deterministic functions of cortical acetylcholine. Eur J Neurosci 2014, 39:1912-1920.
37. Kurzban R., Duckworth A., Kable J.W., Myers J. An opportunity cost model of subjective effort and task performance. Behav Brain Sci 2013, 36:661-679.
38. Berry A.S., Demeter E., Sabhapathy S., English B.A., Blakely R.D., Sarter M., Lustig C. Disposed to distraction: genetic variation in the cholinergic system influences distractibility but not time-on-task effects. J Cogn Neurosci 2014, 26:1981-1991.
39. Thiele A. Muscarinic signaling in the brain. Annu Rev Neurosci 2013, 36:271-294.
40. Roiser J.P., Elliott R., Sahakian B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2011, 37:117-136.
41. Gold J.M., Fuller R.L., Robinson B.M., Braun E.L., Luck S.J. Impaired top-down control of visual search in schizophrenia. Schizophr Res 2007, 94:148-155.
42. Luck S.J., Ford J.M., Sarter M., Lustig C. CNTRICS final biomarker selection: control of attention. Schizophr Bull 2011, 38:53-61.
43. Sarter M., Albin R.L., Kucinski A., Lustig C. Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol 2014, 257:120-129.
44. Allcock L.M., Rowan E.N., Steen I.N., Wesnes K., Kenny R.A., Burn D.J. Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:110-115.